Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemor

Monday, February 13, 2017   (0 Comments)
Posted by: Kate Oesterle
Share |
GAITHERSBURG, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. today announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to develop monoclonal antibody therapeutics for viral hemorrhagic fever. This task order will utilize the company's Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland. Using monoclonal antibodies from Mapp Biopharmaceutical Inc., the company will conduct technology transfer of process materials and information, perform process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance. The task order consists of a 36-month period of performance with a base task order valued at $7.4 million and options that, if executed, will bring the total task order value over three years to up to $30.5 million.

Read full article here.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal